Cellaïon

Cellaïon is a Belgian biotechnology company based in Mont-Saint-Guibert, Wallonia.

Founded in March 2021, the company focuses on developing advanced cell-based therapies aimed at repairing tissues and regenerating organs, particularly for life-threatening liver diseases. Cellaïon’s mission is to prolong life through innovative cell signaling technology. The company’s flagship product, HepaStem®, is an allogeneic advanced therapy derived from liver stem cells. It utilizes cell signaling technology to provide immunomodulatory and antifibrotic effects, helping to halt disease progression and promote liver recovery. HepaStem® is currently in Phase IIb clinical development, targeting conditions such as Acute-on-Chronic Liver Failure (ACLF), acute alcoholic hepatitis, and progressive non-alcoholic steatohepatitis (NASH). Cellaïon collaborates with pharmaceutical partners to develop treatments based on its proprietary Signaling Cell Platform. The company has successfully raised significant funding to support its mission, positioning itself as a key player in the field of regenerative medicine for liver diseases.